175 related articles for article (PubMed ID: 15292932)
1. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
Calvet L; Santos A; Valent A; Terrier-Lacombe MJ; Opolon P; Merlin JL; Aubert G; Morizet J; Schellens JH; Bénard J; Vassal G
Br J Cancer; 2004 Sep; 91(6):1205-12. PubMed ID: 15292932
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
3. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
[TBL] [Abstract][Full Text] [Related]
4. In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
Santos A; Calvet L; Terrier-Lacombe MJ; Larsen A; Bénard J; Pondarré C; Aubert G; Morizet J; Lavelle F; Vassal G
Cancer Res; 2004 May; 64(9):3223-9. PubMed ID: 15126363
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Kaneko S; Ishibashi M; Kaneko M
Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
7. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
Calvet L; Geoerger B; Regairaz M; Opolon P; Machet L; Morizet J; Joseph JM; Elie N; Vassal G
Oncogene; 2006 May; 25(22):3150-9. PubMed ID: 16501609
[TBL] [Abstract][Full Text] [Related]
8. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
10. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
[TBL] [Abstract][Full Text] [Related]
11. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
[TBL] [Abstract][Full Text] [Related]
14. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Kaneko M; Kaneko S; Suzuki K
Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oral irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
[TBL] [Abstract][Full Text] [Related]
16. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
18. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
19. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer GL; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JD; Haber M
Mol Cancer Ther; 2005 Apr; 4(4):547-53. PubMed ID: 15827327
[TBL] [Abstract][Full Text] [Related]
20. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]